

Source CCNMatthews
Date 06/14/2005
Time 05:00:25 AM
Company BIOPOTENTIAL CAPITAL INC.
Title Biopotential Capital Inc. Announces the Appointment of Dr. Thomas J. Hudson to Its Scientific Advisory Board

DMIS Processed No CDNX Symbol: BPI
Exchange: VENTURE Symbol: BPI
Exchange: Symbol:
Exchange: Symbol:

Press Release

[IMAGE] [IMAGE]

NEWS RELEASE TRANSMITTED BY CCNMatthewsFOR: BIOPOTENTIAL CAPITAL INC.TSX
VENTURE SYMBOL: BPI

June 14, 2005Biopotential Capital Inc. Announces the Appointment of Dr. Thomas J. Hudson to
Its Scientific Advisory BoardCALGARY, ALBERTA--(CCNMatthews - June 14, 2005) -
Biopotential Capital Inc.,
listed on the TSX Venture Exchange (TSX-V: BPI), is pleased to announce the
appointment of Dr. Thomas J. Hudson to its Scientific Advisory Board.

Dr. Hudson is an Associate Professor & Associate Physician, Departments of
Medicine & Human Genetics at McGill University and founder & Director of the
McGill University and Genome Quebec Innovation Centre. Dr. Hudson teaches in
the departments of Human Genetics and Medicine at McGill University and
practices medicine at the McGill University Health Centre - Montreal General
Hospital (Division of Immunology and Allergy).

Dr. Hudson is internationally renowned for his work in Genomics and is past
Assistant-Director of the Whitehead Institute/MIT Center for Genome Research
and past Chair of the Science Committee of Genome Canada. At the Whitehead
Institute, Dr. Hudson led the effort to generate dense physical and gene maps
of the human and mouse genomes. He is a leader in the development and
applications of robotic systems and DNA-chip based methodologies for genome
research. In June 1996, he founded the Montreal Genome Centre based at the
McGill University Health Centre Research Institute. In 2003, this group

expanded to become the McGill University and Genome Quebec Innovation Centre. Dr. Hudson and his team were founding members of the International Haplotype Map Consortium. Dr. Hudson's interests in human genetic diseases focus on the dissection of complex genetic diseases. Ongoing disease projects in Dr. Hudson's laboratory include the search for genes predisposing to lupus, inflammatory bowel disease, coronary artery disease, asthma, and diabetes. The laboratory is also using the DNA-chip technology in order to characterize breast and ovarian cancer.

Dr. Hudson is editor-in-chief of the journal Human Genetics. He has received numerous prestigious awards, including the Andre-Dupont 2002 Young Investigator Award given by Quebec's Clinical Research Club, an Investigator Award from the Canadian Institutes of Health Research, a Burroughs-Wellcome Clinician-Scientist Award, The 2002 Prix de la Sante from the Armand-Frappier Foundation, the 2001 Young Scientist Award by the Genetics Society of Canada, the 2000 Scientist of the Year by Radio-Canada and the 1999 Canada Top 40 Under 40.

One of Canada's top scientist and a Jonquiere, Quebec native, Dr. Hudson studied medicine at the Universite de Montreal and completed his post-doctorate studies at Boston's MIT and Whitehead Institute.

Dr. Hudson has made numerous scientific achievements including recent cloning of a gene for a neurodegenerative disease called ARSACS, a disease that affects 300 individuals in northeastern Quebec; mapping of a gene causing infantile cirrhosis and identification of mutations involved in diabetes and lipid disorders.

Dr. Hudson was included in a cover story grouping of "Great Canadians" by Maclean's that also featured Supreme Court chief justice Beverley McLachlin and ABC News anchor Peter Jennings. According to Maclean's, Hudson is "one of the founding fathers of the much-heralded New Age research into humanity's chemical code, its genome."

Dr. Hudson stated that he is pleased to join Osta's scientific advisory board.

"It is a great pleasure and honor for us to have one of the world's leading authorities on genomics research and a world renowned scientist like Dr. Hudson joining our Scientific Advisory Board. His addition to our team is very synergistic with our research & development programs and is invaluable as he brings vast knowledge in genomics research as well as solid clinical expertise" says Dr. Ajay Gupta, Biopotential's Chairman & CEO.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release and does not accept responsibility for the adequacy or accuracy for this release.

Certain information in this press release is forward-looking and is subject to numerous risks and uncertainties. By their nature, such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include actions of Biopotential's competitors, and those inherent in scientific research and development.

- 30 -FOR FURTHER INFORMATION PLEASE CONTACT:
Biopotential Capital Inc.
Alain Geahchan

Director, Investor Relations
(514) 567-5505

INDUSTRY: FIS - Financial Services
SUBJECT: BRD - BOARD OF DIRECTORS

FOR: BIOPOTENTIAL CAPITAL INC.
TSX VENTURE SYMBOL: BPI

[IMAGE]

[IMAGE]

[IMAGE]